Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Eli Lilly (LLY) edged 1% higher in morning Tuesday trading after new data pointed to greater weight and blood-sugar reductions from its oral Foundayo treatment than oral semaglutide at higher doses.The analysis examined 17.2 mg of Foundayo, or orforglipron, in adults with type 2 diabetes. At week 5…
LLY Eli Lilly: Foundayo Shows Greater Weight Loss and A1C Reduction vs. Oral Semaglutide 25 mg in Indirect Comparison ⠀ • At 52 weeks, Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction. • Analysis used data from ACHIEVE-3 and PIONEER PLUS rather than a direct head-to
Reuters briefs says Foundayo (orforglipron) 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1c reduction versus oral semaglutide 25 mg at 52 weeks in an indirect treatment comparison (Achieve-3).